Company news
Tempest Therapeutics, Inc. news in 2021
Tempest Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab
November 17, 2021
Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer
November 11, 2021
Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights
November 9, 2021
Tempest to Present at Two Upcoming Investor Conferences in November
November 8, 2021
Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
September 30, 2021
Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche
September 19, 2021
Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights
August 11, 2021
Tempest Announces Appointment of Ronit Simantov, M.D. to its Board of Directors
August 8, 2021
Tempest Announces Appointment of Christine Pellizzari to its Board of Directors
June 30, 2021
Tempest and Millendo Announce Stockholder Approval of Merger
June 21, 2021
Tempest and Millendo Announce Proposed Merger Agreement
March 28, 2021
Decks in 2021
- Millendo Therapeutics — Merger or Acquisition (March 2021)
Merger or acquisition · 23 slides · Mar 29, 2021